ingelheim
Boehringer eyes Ofev success in IPF and beyond
March 16, 2015Sales and Marketing Boehringer, Esbriet, Roche, ingelheim, inpulsis, ipd, ofev
Experts say the launch of Boehringer Ingelheim’s new treatment for idiopathic pulmonary fibrosis (IPF) offers stiff competition to Roche’s Esbriet …
Boehringer gains EU approval for Ofev
January 19, 2015Sales and Marketing Boehringer, Esbriet, IPF, InterMune, ingelheim, nintedanib, ofev
The European Commission has approved Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis (IPF). The approval follows the …
Boehringer gets NICE nod for Pradaxa
December 16, 2014Sales and Marketing Boehringer, NHS, NICE, Pradaxa, VTE, dagibatran, ingelheim, warfarin
NICE has confirmed a recommendation for Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa, as a treatment for blood clots in …
NICE recommends new indication for troubled Pradaxa
October 31, 2014Sales and Marketing Boehringer, NHS, NICE, Pradaxa, dabigatran, ingelheim, warfarin
NICE has recommended Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa for treating and preventing potentially-fatal blood clots in the legs …
Boehringer’s lung cancer drug gets EMA nod
September 29, 2014Sales and Marketing Boehringer, IPF, docetaxel, ingelheim, lung cancer, nintedanib
The EMA has issued a positive opinion for the approval of Boehringer Ingelheim’s nintedanib in combination with docetaxel for the …
Latest content
Five Facts about cardiovascular disease
